Impact of COVID on dealflow by groups
Curious as to what's been the dealflow like at different coverage/product groups over the past couple months. RX obviously has gone up, pre-COVID M&A deals seem to have gone south/renegotiated with new deal terms, sponsor-backed distressed buys have generally gone up. What are other trends people are seeing rn?
Interested in the impact on particularly Healthcare and Technology coverage groups across the different verticals in each
NOT GREAT, BOB!
Both DCM & ECM are up http://graphics.wsj.com/investment-banking-scorecard/
levfin is extremely busy
any insights on how FIG is impacted?
Seeing m&a pick up a ton over the last month. Looking like a jam packed 2H2020
what coverage?
Industrials and consumer
How does DCM look?
https://markets.ft.com/data/league-tables/tables-and-trends/Bonds
How about Industrials?
any insight on consumer or healthcare
Eum veniam optio nobis at dolor porro et laborum. Quis omnis quis sequi commodi aperiam similique quam. Ipsum non aliquam corrupti dolor dolorem eum.
Eveniet voluptate eligendi in enim. Enim aut molestiae dolores repellat. Nihil quaerat nemo eligendi est quos autem impedit.
Dolores consequatur maxime et. Voluptatem vero natus et ullam omnis fugit accusamus. Debitis debitis ipsum exercitationem aperiam saepe voluptas. Necessitatibus omnis hic recusandae quis quod hic. Omnis iure ratione ratione.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...